In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Impax, Shire settle litigation regarding Adderall XR

Executive Summary

Shire Pharmaceuticals and Impax Laboratories (generics) have reached a settlement concerning the former's attention deficit hyperactivity disorder treatment Adderall XR. Under the agreement, Impax can sell a generic version of the drug in the US starting no later than January 1, 2010.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
    • Generic Drugs
    • Specialty Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Marketing-Licensing

Related Companies

Advertisement
UsernamePublicRestriction

Register